302 related articles for article (PubMed ID: 28039941)
1. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.
Fung P; Bedogni G; Bedogni A; Petrie A; Porter S; Campisi G; Bagan J; Fusco V; Saia G; Acham S; Musto P; Petrucci MT; Diz P; Colella G; Mignogna MD; Pentenero M; Arduino P; Lodi G; Maiorana C; Manfredi M; Hallberg P; Wadelius M; Takaoka K; Leung YY; Bonacina R; Schiødt M; Lakatos P; Taylor T; De Riu G; Favini G; Rogers SN; Pirmohamed M; Nicoletti P; ; Fedele S
Oral Dis; 2017 May; 23(4):477-483. PubMed ID: 28039941
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy.
Fleisher KE; Jolly A; Venkata UD; Norman RG; Saxena D; Glickman RS
J Oral Maxillofac Surg; 2013 Mar; 71(3):513-9. PubMed ID: 22999296
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
7. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
[TBL] [Abstract][Full Text] [Related]
8. Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.
Park JH; Kwoen MJ; Lee JR; Kim KS; Lee HJ; Kim JW; Lee H
Front Endocrinol (Lausanne); 2021; 12():774820. PubMed ID: 34956086
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
10. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
[TBL] [Abstract][Full Text] [Related]
11. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Gabbert TI; Hoffmeister B; Felsenberg D
J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
14. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
15. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients.
Walter C; Al-Nawas B; Frickhofen N; Gamm H; Beck J; Reinsch L; Blum C; Grötz KA; Wagner W
Head Face Med; 2010 Jul; 6():11. PubMed ID: 20615236
[TBL] [Abstract][Full Text] [Related]
17. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
[TBL] [Abstract][Full Text] [Related]
18. Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.
Maines E; Monti E; Doro F; Morandi G; Cavarzere P; Antoniazzi F
J Bone Miner Metab; 2012 Jul; 30(4):434-8. PubMed ID: 22065238
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
[TBL] [Abstract][Full Text] [Related]
20. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
